TPST
Tempest Therapeutics Inc.
$9.45
-$0.68(-6.71%)
45
Overall
--
Value
45
Tech
--
Quality
Market Cap
$44.71M
Volume
89.08K
52W Range
$5.36 - $20.67
Target Price
$9.00
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | $295.0K | -- | -- | -- | -- | -- | ||
| Total Revenue | $295.0K | -- | -- | -- | -- | -- | ||
| COST OF GOODS SOLD | ||||||||
| Cost of Revenue | $-790.0K | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||
| Gross Profit | $-495.0K | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $84.3M | $19.3M | $27.0M | $34.6M | $29.2M | $42.0M | ||
| Research & Development | $78.4M | $14.4M | $17.2M | $22.5M | $17.5M | $28.5M | ||
| Research Expense | $78.4M | $14.4M | $17.2M | $22.5M | $17.5M | $28.5M | ||
| Selling, General & Administrative | $6.0M | $4.9M | $9.8M | $12.1M | $11.7M | $13.6M | ||
| Selling & Marketing Expenses | $27.7M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $6.0M | $4.9M | $9.8M | $12.1M | $11.7M | $13.6M | ||
| Salaries & Wages | $-762.0K | -- | -- | -- | $2.5M | $5.3M | ||
| Depreciation & Amortization | $-1.6M | $339.0K | $374.0K | $638.0K | $381.0K | $389.0K | ||
| Depreciation & Amortization | $-1.6M | $339.0K | $374.0K | $638.0K | $381.0K | $389.0K | ||
| Other Operating Expenses | -- | $-200.0K | $-246.0K | $-357.0K | $-273.0K | $-316.0K | ||
| OPERATING INCOME | ||||||||
| Operating income | $-84.3M | $-19.3M | $-27.0M | $-34.6M | $-29.2M | $-42.0M | ||
| EBITDA | $-84.3M | $-18.9M | $-26.6M | $-33.5M | $-31.6M | $-44.4M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | $288.0K | -- | $1.3M | $1.6M | $1.4M | -- | ||
| Intinc | -- | $155.0K | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-288.0K | $155.0K | $-1.3M | $1.0M | $349.0K | -- | ||
| Other Income/Expense | $-28.0K | $-90.0K | $34.0K | $-51.0K | $-1.1M | $-1.5M | ||
| Other Special Charges | $28.0K | $90.0K | $-34.0K | $549.0K | $1.1M | $1.5M | ||
| SPECIAL ITEMS | ||||||||
| Restructring And Mn A Income | $4.0M | -- | -- | -- | -- | -- | ||
| Special Income Charges | $-4.0M | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | $-400.0K | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-84.3M | $-19.2M | $-27.0M | $-34.1M | $-32.0M | $-44.8M | ||
| Pre-Tax Income | $-84.6M | $-19.2M | $-28.3M | $-35.7M | $-28.0M | $-40.5M | ||
| INCOME TAX | ||||||||
| Tax Provision | $67.0K | $-1.8M | $-3.9M | $-2.7M | $-2.5M | $-3.0M | ||
| NET INCOME | ||||||||
| Net Income | $-84.6M | $-19.2M | $-28.3M | $-35.7M | $-29.5M | $-41.8M | ||
| Net Income (Continuing Operations) | $-84.6M | $-19.2M | $-28.3M | $-35.7M | $-29.5M | $-41.8M | ||
| Net Income (Discontinued Operations) | $-84.6M | $-19.2M | $-28.3M | $-35.7M | $-29.5M | $-41.8M | ||
| Net Income (Common Stockholders) | $-84.6M | $-19.2M | $-28.3M | $-35.7M | $-29.5M | $-41.8M | ||
| Normalized Income | -- | -- | $-32.2M | -- | -- | $-43.5M | ||
| TOTALS | ||||||||
| Total Expenses | $84.3M | $19.3M | $27.0M | $34.6M | $29.2M | $42.0M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $262.8K | $96.7K | $291.6K | $888.4K | $15.4M | $27.9M | ||
| Average Shares Outstanding (Diluted) | -- | -- | $291.6K | $888.4K | $15.4M | $27.9M | ||
| Shares Outstanding | $4.4M | $97.7K | $4.4M | $812.4K | $22.2M | $45.5M | ||
| Basic EPS | -- | $-376.35 | $-97.11 | $-40.17 | $-1.91 | $-1.5 | ||
| Basic EPS (Continuing Operations) | -- | $-376.35 | $-97.11 | $-40.17 | $-1.91 | $-1.5 | ||
| Diluted EPS | $-321.81 | $-376.35 | $-97.11 | $-40.17 | $-1.91 | $-1.5 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-97.11 | $-40.17 | $-1.91 | $-1.5 | ||
| OTHER METRICS | ||||||||
| Earnings from equity interest | $-1.0M | -- | -- | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $-1.0M | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | $100.0K | -- | -- | -- | -- | -- | ||
| Minority Interests | $8.0K | -- | -- | -- | -- | -- | ||
| Other Gand A | $6.0M | $4.9M | $9.8M | $12.1M | $11.7M | $13.6M | ||
| Other Write Down | $-1.4M | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $6.0M | -- | -- | -- | -- | -- | ||
| Selling Expense | $27.7M | -- | -- | -- | -- | -- | ||
| Restruct | $4.0M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TPST | $9.45 | -6.7% | 89.08K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tempest Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW